Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial

Published:2012-01 Issue:1 Volume:46 Page:64-71
ISSN:0022-3956
Container-title:Journal of Psychiatric Research
language:en
Short-container-title:Journal of Psychiatric Research

Author:

Tran Pierre,Skolnick Phil,Czobor Pal,Huang N.Y.,Bradshaw Mark,McKinney Anthony,Fava Maurizio

Funder

Euthymics Bioscience

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference65 articles.

1. Diagnostic and statistical manual of mental disorders,2000

2. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability;Anderson;Journal of Affective Disorders,2000

3. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat;Axel;Neuropsychopharmacology,2010

4. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression;Bech;British Journal of Psychiatry,2000

5. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study;Blier;American Journal of Psychiatry,2010

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ansofaxine hydrochloride inhibits tumor growth and enhances Anti-TNFR2 in murine colon cancer model;Frontiers in Pharmacology;2023-12-14

2. Designing multi-target drugs for the treatment of major depressive disorder;Expert Opinion on Drug Discovery;2023-05-19

3. A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder;Translational Psychiatry;2023-05-10

4. Discovery of Multi-Functional Lead Compounds Originating from Traditional Chinese Medicine for Developing Anti-Depressive Agents via Virtual Screening;Letters in Drug Design & Discovery;2023-04-18

5. Efficacy, Tolerability, and Safety of Toludesvenlafaxine for the Treatment of Major Depressive Disorder—A Narrative Review;Pharmaceuticals;2023-03-08